Led by Eliptica CSO and co-founder Markus Ralser, the study profiles INS-1 β cells and reveals rapid regulation of fatty-acid biosynthesis in response to glucose stimulation. The work shows how quantitative proteomics can capture dynamic biological responses, reinforcing the value of protein measurements as a direct readout of functional physiology and disease-relevant biology.